Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1991 Oct;74(2):304–309.

TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis.

F Y Liew 1, Y Li 1, D M Yang 1, A Severn 1, F E Cox 1
PMCID: PMC1384609  PMID: 1748478

Abstract

Earlier studies have demonstrated that mice injected subcutaneously or intramuscularly with leishmanial antigens develop significantly exacerbated disease compared with unimmunized controls when challenged with the cutaneous protozoan parasites Leishmania major. We report here that this disease enhancement can be prevented, and protective immunity induced, by the incorporation of recombinant tumour necrosis factor (TNF-alpha) in the immunizing inoculum. This effect of TNF-alpha is dose-dependent and is not evident when TNF-alpha and the antigens are injected into separate sites. Furthermore, TNF-alpha injected together with p183, a peptide known to preferentially stimulate Th2 cells and disease exacerbation in H-2d mice, activates spleen and lymph node cells secreting more interferon-gamma (IFN-gamma) and less interleukin-4 (IL-4) and induces a modest but significant degree of resistance against L. major infection in highly susceptible BALB/c mice.

Full text

PDF
304

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Trans R Soc Trop Med Hyg. 1982;76(5):646–649. doi: 10.1016/0035-9203(82)90232-2. [DOI] [PubMed] [Google Scholar]
  2. Carter K. C., Gallagher G., Baillie A. J., Alexander J. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur J Immunol. 1989 Apr;19(4):779–782. doi: 10.1002/eji.1830190432. [DOI] [PubMed] [Google Scholar]
  3. Clayberger C., DeKruyff R. H., Fay R., Cantor H. Identification of a unique B-cell-stimulating factor produced by a cloned dendritic cell. Proc Natl Acad Sci U S A. 1985 Jan;82(1):183–187. doi: 10.1073/pnas.82.1.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gao X. M., Liew F. Y., Bottomly K., Meager A., Tite J. P. Clonal analysis of the relationship between class II MHC-restricted cytolysis and lymphokine secretion in murine L3T4+ T cells. Immunology. 1991 Feb;72(2):256–260. [PMC free article] [PubMed] [Google Scholar]
  5. Green S. J., Crawford R. M., Hockmeyer J. T., Meltzer M. S., Nacy C. A. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol. 1990 Dec 15;145(12):4290–4297. [PubMed] [Google Scholar]
  6. Handman E., Mitchell G. F. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5910–5914. doi: 10.1073/pnas.82.17.5910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Howard J. G., Nicklin S., Hale C., Liew F. Y. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol. 1982 Nov;129(5):2206–2212. [PubMed] [Google Scholar]
  8. Jardim A., Alexander J., Teh H. S., Ou D., Olafson R. W. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med. 1990 Aug 1;172(2):645–648. doi: 10.1084/jem.172.2.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Liew F. Y. Functional heterogeneity of CD4+ T cells in leishmaniasis. Immunol Today. 1989 Feb;10(2):40–45. doi: 10.1016/0167-5699(89)90302-2. [DOI] [PubMed] [Google Scholar]
  10. Liew F. Y., Li Y., Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol. 1990 Dec 15;145(12):4306–4310. [PubMed] [Google Scholar]
  11. Liew F. Y., Millott S. M., Schmidt J. A. A repetitive peptide of Leishmania can activate T helper type 2 cells and enhance disease progression. J Exp Med. 1990 Nov 1;172(5):1359–1365. doi: 10.1084/jem.172.5.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Liew F. Y., Millott S., Li Y., Lelchuk R., Chan W. L., Ziltener H. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis. Eur J Immunol. 1989 Jul;19(7):1227–1232. doi: 10.1002/eji.1830190712. [DOI] [PubMed] [Google Scholar]
  13. Liew F. Y., Parkinson C., Millott S., Severn A., Carrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology. 1990 Apr;69(4):570–573. [PMC free article] [PubMed] [Google Scholar]
  14. Massa P. T., Schimpl A., Wecker E., ter Meulen V. Tumor necrosis factor amplifies measles virus-mediated Ia induction on astrocytes. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7242–7245. doi: 10.1073/pnas.84.20.7242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Preston P. M., Dumonde D. C. Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse. Clin Exp Immunol. 1976 Jan;23(1):126–138. [PMC free article] [PubMed] [Google Scholar]
  16. Russell D. G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol. 1988 Feb 15;140(4):1274–1279. [PubMed] [Google Scholar]
  17. Scott P., Natovitz P., Coffman R. L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med. 1988 Nov 1;168(5):1675–1684. doi: 10.1084/jem.168.5.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol. 1987 Jul 1;139(1):221–227. [PubMed] [Google Scholar]
  19. Talmadge J. E., Phillips H., Schneider M., Rowe T., Pennington R., Bowersox O., Lenz B. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res. 1988 Feb 1;48(3):544–550. [PubMed] [Google Scholar]
  20. Taylor P. M., Meager A., Askonas B. A. Influenza virus-specific T cells lead to early interferon gamma in lungs of infected hosts: development of a sensitive radioimmunoassay. J Gen Virol. 1989 Apr;70(Pt 4):975–978. doi: 10.1099/0022-1317-70-4-975. [DOI] [PubMed] [Google Scholar]
  21. Titus R. G., Sherry B., Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med. 1989 Dec 1;170(6):2097–2104. doi: 10.1084/jem.170.6.2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yang D. M., Fairweather N., Button L. L., McMaster W. R., Kahl L. P., Liew F. Y. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol. 1990 Oct 1;145(7):2281–2285. [PubMed] [Google Scholar]
  23. Yang D. M., Rogers M. V., Liew F. Y. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology. 1991 Jan;72(1):3–9. [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES